{
  "success": true,
  "pagesUsed": [
    3,
    4,
    5,
    11,
    12,
    13,
    14,
    23,
    24,
    25,
    26
  ],
  "modelUsed": "gemini-3-flash-preview",
  "objectivesEndpoints": {
    "objectives": [
      {
        "id": "obj_1",
        "name": "Primary Safety Objective (All Cohorts)",
        "text": "To describe the safety profile of 20vPnC in adults 18 years of age and older.",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_1",
          "ep_2",
          "ep_3",
          "ep_4"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_2",
        "name": "Primary Immunogenicity Objective 1 - Cohort 1",
        "text": "To demonstrate that the immune responses to the 13 serotypes in 13vPnC (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) induced by 20vPnC in adults 60 years of age and older are noninferior to the immune response induced by 13vPnC.",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_5"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_3",
        "name": "Primary Immunogenicity Objective 2 - Cohort 1",
        "text": "To demonstrate that the immune responses to the 7 additional serotypes (8, 10A, 11A, 12F, 15B, 22F, and 33F) induced by 20vPnC in adults 60 years of age and older are noninferior to the immune response induced by PPSV23.",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_5"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_4",
        "name": "Secondary Objective - Cohort 2",
        "text": "To demonstrate that the immune responses to the 20 serotypes in 20vPnC induced in adults 50 through 59 years of age are noninferior to the immune responses induced by 20vPnC in adults 60 through 64 years of age.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_6"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_5",
        "name": "Secondary Objective - Cohort 3",
        "text": "To demonstrate that the immune responses to the 20 serotypes in 20vPnC induced in adults 18 through 49 years of age are noninferior to the immune responses induced by 20vPnC in adults 60 through 64 years of age.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_7"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_6",
        "name": "Secondary Objective - All Cohorts",
        "text": "To describe the immune responses to 20vPnC in adults 60 years of age and older, 50 through 59 years of age, and 18 through 49 years of age.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_8",
          "ep_9",
          "ep_10"
        ],
        "instanceType": "Objective"
      }
    ],
    "endpoints": [
      {
        "id": "ep_1",
        "name": "Prompted Local Reactions",
        "text": "Reported prompted local reactions (redness, swelling, and pain at the injection site) within 10 days after vaccination.",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_2",
        "name": "Prompted Systemic Events",
        "text": "Reported prompted systemic events (fever, headache, fatigue, muscle pain, and joint pain) within 7 days after vaccination.",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_3",
        "name": "Adverse Events",
        "text": "Reported adverse events (AEs) within 1 month after vaccination.",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_4",
        "name": "SAEs and NDCMCs",
        "text": "Reported serious adverse events (SAEs) and newly diagnosed chronic medical conditions (NDCMCs) within 6 months after vaccination.",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_5",
        "name": "Primary Immunogenicity Endpoint - Cohort 1",
        "text": "Serotype-specific opsonophagocytic activity (OPA) titers 1 month after vaccination.",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_6",
        "name": "Secondary Endpoint - Cohort 2",
        "text": "Serotype-specific OPA titers 1 month after vaccination.",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_7",
        "name": "Secondary Endpoint - Cohort 3",
        "text": "Serotype-specific OPA titers 1 month after vaccination.",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_8",
        "name": "OPA Fold Rise",
        "text": "Fold rise in serotype-specific OPA titers from before to 1 month after vaccination.",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_9",
        "name": ">=4-Fold OPA Rise",
        "text": ">=4-Fold rise in serotype-specific OPA titers from before to 1 month after vaccination.",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_10",
        "name": "OPA >=LLOQ",
        "text": "Serotype-specific OPA titers greater than or equal to the lower limit of quantitation (>=LLOQ) 1 month after vaccination.",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      }
    ],
    "estimands": [
      {
        "id": "est_1",
        "name": "Primary Immunogenicity Estimand - Cohort 1",
        "populationSummary": "Adults 60 years of age and older with no history of pneumococcal vaccination (Cohort 1) Summary measure: Geometric mean ratio (GMR).",
        "analysisPopulationId": "est_1_pop",
        "variableOfInterestId": "ep_5",
        "interventionIds": [
          "est_1_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_1",
            "name": "Protocol deviation",
            "text": "Major protocol deviations affecting the immunogenicity assessment",
            "strategy": "Hypothetical",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_2",
            "name": "Non-study vaccination",
            "text": "Receipt of prohibited non-study pneumococcal vaccines",
            "strategy": "Hypothetical",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_3",
            "name": "Withdrawal/Discontinuation",
            "text": "Subject withdraws from study before the 1-month blood draw",
            "strategy": "Hypothetical",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "20vPnC followed by Saline vs 13vPnC followed by PPSV23",
        "analysisPopulation": "Adults 60 years of age and older with no history of pneumococcal vaccination (Cohort 1)",
        "variableOfInterest": "Serotype-specific opsonophagocytic activity (OPA) titers 1 month after vaccination",
        "summaryMeasure": "Geometric mean ratio (GMR)"
      },
      {
        "id": "est_2",
        "name": "Primary Safety Estimand - Local Reactions",
        "populationSummary": "Adults 18 years of age and older (All Cohorts) Summary measure: Percentage of subjects.",
        "analysisPopulationId": "est_2_pop",
        "variableOfInterestId": "ep_1",
        "interventionIds": [
          "est_2_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_4",
            "name": "Treatment discontinuation",
            "text": "Subject discontinues study before the 10-day diary period is complete",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "20vPnC vs Control (13vPnC or Saline/PPSV23)",
        "analysisPopulation": "Adults 18 years of age and older (All Cohorts)",
        "variableOfInterest": "Reported prompted local reactions within 10 days",
        "summaryMeasure": "Percentage of subjects"
      },
      {
        "id": "est_3",
        "name": "Secondary Immunogenicity Estimand - Cohort 2",
        "populationSummary": "Adults 50 through 59 years of age (Cohort 2) compared to adults 60 through 64 years of age Summary measure: Geometric mean ratio (GMR).",
        "analysisPopulationId": "est_3_pop",
        "variableOfInterestId": "ep_6",
        "interventionIds": [
          "est_3_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_5",
            "name": "Missing data",
            "text": "Missing immunogenicity data at the 1-month visit",
            "strategy": "Hypothetical",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "20vPnC in Cohort 2 vs 20vPnC in Cohort 1 (60-64 years)",
        "analysisPopulation": "Adults 50 through 59 years of age (Cohort 2) compared to adults 60 through 64 years of age",
        "variableOfInterest": "Serotype-specific OPA titers 1 month after vaccination",
        "summaryMeasure": "Geometric mean ratio (GMR)"
      }
    ],
    "summary": {
      "primaryObjectives": 3,
      "secondaryObjectives": 3,
      "exploratoryObjectives": 0,
      "totalEndpoints": 10,
      "totalEstimands": 3
    }
  },
  "rawResponse": {
    "objectives": [
      {
        "id": "obj_1",
        "name": "Primary Safety Objective (All Cohorts)",
        "text": "To describe the safety profile of 20vPnC in adults 18 years of age and older.",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_1",
          "ep_2",
          "ep_3",
          "ep_4"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_2",
        "name": "Primary Immunogenicity Objective 1 - Cohort 1",
        "text": "To demonstrate that the immune responses to the 13 serotypes in 13vPnC (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) induced by 20vPnC in adults 60 years of age and older are noninferior to the immune response induced by 13vPnC.",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_5"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_3",
        "name": "Primary Immunogenicity Objective 2 - Cohort 1",
        "text": "To demonstrate that the immune responses to the 7 additional serotypes (8, 10A, 11A, 12F, 15B, 22F, and 33F) induced by 20vPnC in adults 60 years of age and older are noninferior to the immune response induced by PPSV23.",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_5"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_4",
        "name": "Secondary Objective - Cohort 2",
        "text": "To demonstrate that the immune responses to the 20 serotypes in 20vPnC induced in adults 50 through 59 years of age are noninferior to the immune responses induced by 20vPnC in adults 60 through 64 years of age.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_6"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_5",
        "name": "Secondary Objective - Cohort 3",
        "text": "To demonstrate that the immune responses to the 20 serotypes in 20vPnC induced in adults 18 through 49 years of age are noninferior to the immune responses induced by 20vPnC in adults 60 through 64 years of age.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_7"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_6",
        "name": "Secondary Objective - All Cohorts",
        "text": "To describe the immune responses to 20vPnC in adults 60 years of age and older, 50 through 59 years of age, and 18 through 49 years of age.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_8",
          "ep_9",
          "ep_10"
        ],
        "instanceType": "Objective"
      }
    ],
    "endpoints": [
      {
        "id": "ep_1",
        "name": "Prompted Local Reactions",
        "text": "Reported prompted local reactions (redness, swelling, and pain at the injection site) within 10 days after vaccination.",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_2",
        "name": "Prompted Systemic Events",
        "text": "Reported prompted systemic events (fever, headache, fatigue, muscle pain, and joint pain) within 7 days after vaccination.",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_3",
        "name": "Adverse Events",
        "text": "Reported adverse events (AEs) within 1 month after vaccination.",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_4",
        "name": "SAEs and NDCMCs",
        "text": "Reported serious adverse events (SAEs) and newly diagnosed chronic medical conditions (NDCMCs) within 6 months after vaccination.",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_5",
        "name": "Primary Immunogenicity Endpoint - Cohort 1",
        "text": "Serotype-specific opsonophagocytic activity (OPA) titers 1 month after vaccination.",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_6",
        "name": "Secondary Endpoint - Cohort 2",
        "text": "Serotype-specific OPA titers 1 month after vaccination.",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_7",
        "name": "Secondary Endpoint - Cohort 3",
        "text": "Serotype-specific OPA titers 1 month after vaccination.",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_8",
        "name": "OPA Fold Rise",
        "text": "Fold rise in serotype-specific OPA titers from before to 1 month after vaccination.",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_9",
        "name": ">=4-Fold OPA Rise",
        "text": ">=4-Fold rise in serotype-specific OPA titers from before to 1 month after vaccination.",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_10",
        "name": "OPA >=LLOQ",
        "text": "Serotype-specific OPA titers greater than or equal to the lower limit of quantitation (>=LLOQ) 1 month after vaccination.",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      }
    ],
    "estimands": [
      {
        "id": "est_1",
        "name": "Primary Immunogenicity Estimand - Cohort 1",
        "populationSummary": "Adults 60 years of age and older with no history of pneumococcal vaccination (Cohort 1) Summary measure: Geometric mean ratio (GMR).",
        "analysisPopulationId": "est_1_pop",
        "variableOfInterestId": "ep_5",
        "interventionIds": [
          "est_1_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_1",
            "name": "Protocol deviation",
            "text": "Major protocol deviations affecting the immunogenicity assessment",
            "strategy": "Hypothetical",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_2",
            "name": "Non-study vaccination",
            "text": "Receipt of prohibited non-study pneumococcal vaccines",
            "strategy": "Hypothetical",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_3",
            "name": "Withdrawal/Discontinuation",
            "text": "Subject withdraws from study before the 1-month blood draw",
            "strategy": "Hypothetical",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "20vPnC followed by Saline vs 13vPnC followed by PPSV23",
        "analysisPopulation": "Adults 60 years of age and older with no history of pneumococcal vaccination (Cohort 1)",
        "variableOfInterest": "Serotype-specific opsonophagocytic activity (OPA) titers 1 month after vaccination",
        "summaryMeasure": "Geometric mean ratio (GMR)"
      },
      {
        "id": "est_2",
        "name": "Primary Safety Estimand - Local Reactions",
        "populationSummary": "Adults 18 years of age and older (All Cohorts) Summary measure: Percentage of subjects.",
        "analysisPopulationId": "est_2_pop",
        "variableOfInterestId": "ep_1",
        "interventionIds": [
          "est_2_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_4",
            "name": "Treatment discontinuation",
            "text": "Subject discontinues study before the 10-day diary period is complete",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "20vPnC vs Control (13vPnC or Saline/PPSV23)",
        "analysisPopulation": "Adults 18 years of age and older (All Cohorts)",
        "variableOfInterest": "Reported prompted local reactions within 10 days",
        "summaryMeasure": "Percentage of subjects"
      },
      {
        "id": "est_3",
        "name": "Secondary Immunogenicity Estimand - Cohort 2",
        "populationSummary": "Adults 50 through 59 years of age (Cohort 2) compared to adults 60 through 64 years of age Summary measure: Geometric mean ratio (GMR).",
        "analysisPopulationId": "est_3_pop",
        "variableOfInterestId": "ep_6",
        "interventionIds": [
          "est_3_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_5",
            "name": "Missing data",
            "text": "Missing immunogenicity data at the 1-month visit",
            "strategy": "Hypothetical",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "20vPnC in Cohort 2 vs 20vPnC in Cohort 1 (60-64 years)",
        "analysisPopulation": "Adults 50 through 59 years of age (Cohort 2) compared to adults 60 through 64 years of age",
        "variableOfInterest": "Serotype-specific OPA titers 1 month after vaccination",
        "summaryMeasure": "Geometric mean ratio (GMR)"
      }
    ]
  }
}